Imlifidase is a Streptococcus pyogenes-derived cysteine protease that rapidly degrades immunoglobulin G antibodies within 2 to 6 hours of administration.
Please provide your email address to receive an email when new articles are posted on . The mean successfully completed dose increased from 48 mg to 2,723 mg of peanut protein by 48 months. 70% ...
LUND, Sweden, July 11, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that the Australian ...
Topline results were announced from a phase 3 trial evaluating Viaskin ® Peanut patch in peanut allergic children aged 4 to 7 years. Viaskin Peanut patch is an epicutaneous immunotherapy that delivers ...
The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patients Imlifidase is an enzyme that rapidly and efficiently cleaves all types of ...
Based on focus groups with children and young people with peanut allergy, experts have published guidance for clinicians working in the UK’s National Health Service (NHS) to help them safely and ...
A $7,500 Agnesian HealthCare Foundation grant will expand EMDR training and equipment for SSM Health Behavioral Health in Fond du Lac.
I use Eye Movement Desensitization and Reprocessing (EMDR ) Therapy as my primary therapeutic intervention. I specialize in working with adults (ages 18-60) who struggle with the effects of trauma or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results